Loading clinical trials...
Loading clinical trials...
A Multicenter, Open-Label, Phase 2 Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Patients With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy
Conditions
Interventions
Eflapegrastim
Chemotherapy
Locations
5
United States
New York Medical College
Valhalla, New York, United States
Carolinas Medical Center/ Levine Children's Hospital
Charlotte, North Carolina, United States
Levine Children's Health
Charlotte, North Carolina, United States
University Hospitals Cleveland Medical Center
Cleveland, Ohio, United States
UT MD Anderson Cancer Center
Houston, Texas, United States
Start Date
May 20, 2021
Primary Completion Date
October 1, 2027
Completion Date
October 1, 2027
Last Updated
April 27, 2026
NCT07249528
NCT00131014
NCT07489378
NCT07177937
NCT07181681
NCT03050268
Lead Sponsor
Spectrum Pharmaceuticals, Inc
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions